MedTrace Logo

bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

NCT00644579 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2008-03-27

No results posted yet for this study

Summary

As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.

Conditions

  • Cutaneous Warts

Interventions

DRUG

bLAC

bLAC high and low dose and placebo

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • NatImmune A/S

    lead INDUSTRY

Principal Investigators

  • Claus Zachariae, MD · Gentofte Amtssygehus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-12-31
Completion
2009-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00644579 on ClinicalTrials.gov